After several years of development, various countries will offer infants, pregnant women, and seniors therapeutic options to prevent respiratory syncytial virus (RSV) infections in 2023.
Driven by recent governmental authorizations, sales of RSV drugs are estimated to surpass $9 billion by 2029, a sizeable increase from the $1 billion forcasted by GlobalData plc in 2023.
$9 Billion RSV Vaccine Market Share Battle Begins
Fatal MERS-CoV Cases Continue in 2023
While the world focused on one type of coronavirus for four years, another sub-type continues to impact people.
The United Arab Emirates (UAE) recently notified World Health Organization (WHO) of a case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Al Ain City in Abu Dhabi.
This is the UAE's 94th confirmed MERS case and 12th death since July 2013, which indicates this viral respiratory infection has a Case Fatality Ratio of no less than 13%.
Amygdala and Insula Retraining Tied to Reduction in Fatigue With Long COVID
Furthermore, patients randomly assigned to the neuroplasticity program saw significant gains in energy